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Summary The Japanese Respiratory Society (JRS) published the guidelines for the
management of community-acquired pneumonia in 2000. The guidelines set up nine
parameters and criteria for the differential diagnosis of atypical pneumonia and
bacterial pneumonia based on clinical symptoms, physical signs and laboratory data.
To evaluate the performance of these guideline criteria, 91 cases of Chlamydia
pneumoniae (53 cases were pure-C. pneumoniae and 38 cases were mixed-C.
pneumoniae pneumonia), 103 cases of Mycoplasma pneumoniae (86 cases were pure-
M. pneumoniae and 17 cases were mixed-M. pneumoniae pneumonia) and 144 cases
of bacterial (Streptococcus pneumoniae and/or Haemophilus influenzae) pneumonia
were analyzed. The accordance rate for a suspected atypical pneumonia with the
guideline criteria was 84.8% for pure-M. pneumoniae pneumonia and 60.3% for pure-
C. pneumoniae pneumonia, but only 9.0% for bacterial pneumonia, 12.1% for mixed-
C. pneumoniae pneumonia and 16.6% for mixed-M. pneumoniae pneumonia. Overall,
the sensitivity and specificity of the criteria in the JRS guidelines were 75.5% and
90.9%, respectively. Our results indicated that the differentiation of pneumonia in
the JRS guidelines is useful for the diagnosis of M. pneumoniae pneumonia, but
difficult to apply to the diagnosis of C. pneumoniae pneumonia.
& 2004 Elsevier Ltd. All rights reserved.
Introduction
Community-acquired pneumonia (CAP) continues to
be a major medical problem. Since CAP also is a
potentially fatal disease, even in previously healthy
persons, early appropriate antibiotic treatment is
vital. Epidemiologic studies show that in the
combined cause-of-death category, pneumonia
ranks sixth as the leading cause of death in the
United States and fourth in Japan. Because of this
high morbidity, guidelines for CAP management
have been promoted throughout the world during
the past decade. In 1993, the American Thoracic
Society (ATS) established guidelines to assist
primary care physicians in antibiotic selection for
the initial empiric treatment of CAP in adults.1
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Subsequently, in 1998, the Infectious Diseases
Society of America (IDSA) published guidelines for
the treatment of CAP.2 These guidelines were
revised in 2001 and 2003, respectively.3,4 The
recommendations for initial antimicrobial therapy
are based on pathogen probabilities, modifying
factors and the severity of CAP. In Western
countries, there have been many prospective
studies on the etiology of CAP.5–8 These studies
demonstrated that Streptococcus pneumoniae in-
cluding drug-resistant S. pneumoniae (DRSP) and
atypical pathogens including the Chlamydia pneu-
moniae, Mycoplasma pneumoniae and Legionella
species, are the common pathogens. Therefore,
macrolides, doxycycline and fluoroquinolones are
recommended for primary empiric monotherapy or
combined-therapy with b-lactams in both ATS and
IDSA, since each has activity against common
bacterial pathogens and atypical pathogens.3,4
The Japanese Respiratory Society (JRS) has been
developing its guidelines since 1998 and published
CAP guidelines in March 2000.9 In Japan, there have
been three reports on the etiology of CAP among
the Japanese population.10–13 Ishida et al.10,11 were
the first to investigate CAP’s etiology. Subse-
quently, we and Saito et al., respectively, reported
newer data obtained from 200 and 238 patients
with CAP using the same microbiological meth-
ods.12,13 All these studies demonstrated that the
most common pathogen was S. pneumoniae,
followed by Haemophilus influenzae, with the third
or fourth leading pathogens being atypical patho-
gens; i.e., C. pneumoniae or M. pneumoniae. Thus,
in general, the etiology of CAP in Japan does not
differ significantly from that in Western countries
except for the low incidence of Legionella spe-
cies.5–8 The etiologic agent which most clearly
differentiates Japan from Western countries is the
frequency of DRSP.14,15 A recent study found that
the frequency of penicillin-intermediate resistance
S. pneumoniae and penicillin-resistant S. pneumo-
niae combined has been increasing gradually in
Japan.14 Furthermore, about half of S. pneumoniae
cases show strong resistance to erythromycin with
minimum inhibitory concentrations (MICs) greater
than or equal to 256 mg/ml.14 Additionally, these
erythromycin-resistant S. pneumoniae cases also
show strong resistance to tetracycline and new
macrolides such as clarithromycin and azithromy-
cin.14 Marked geographical differences in the
prevalence of both penicillin and macrolide resis-
tance have been observed and the highest rates
have been found in Asia.15 Clinical failure of initial
treatment using macrolides against S. pneumoniae
pneumonia has also been reported in Japan. On the
other hand, fluoroquinolone-resistant S. pneumo-
niae (defined as levofloxacin MIC greater than or
equal to 8 mg/ml) has been detected, but with low
prevalence. However, prevalence is greater in Asia
than in Western countries.15 Therefore, the JRS
recommends the restriction of quinolone usage to
prevent an increase in the frequency of quinolone-
resistant strains to the high frequency of macrolide
or tetracycline-resistant strains. Based on these
facts, the JRS proposed a differential diagnosis
between bacterial pneumonia and atypical pneu-
monia for the selection of an appropriate antibiotic
for the management of mild-to-moderate pneumo-
nia. The guidelines set up nine parameters and
criteria for the differential diagnosis, and JRS
members demonstrated that these guideline criter-
ia were a useful tool for distinguishing between
mycoplasmal and bacterial pneumonia on prelimin-
ary reports.9 However, the parameters and criteria
were made based on the clinical features of M.
pneumoniae pneumonia and there have been no
studies to evaluate patients with another common
atypical pathogen, C. pneumoniae.
In this study, we assessed the Japanese CAP
guidelines with regard to whether we could
distinguish pneumonia with atypical pathogens
including C. pneumoniae and M. pneumoniae from
pneumonia with common bacteria including S.
pneumoniae and H. influenzae.
Subjects and methods
Study population
Adult patients with CAP who visited an outpatient
clinic or were admitted to Kawasaki Medical School
Hospital, Kawasaki Medical School Kawasaki Hospi-
tal or Kurashiki Daiichi Hospital, Okayama, Japan,
between April 1998 and July 2003 were enrolled in
this study. We also included adult patients with CAP
enrolled in a multicenter CAP surveillance study
performed in seven medical schools and their
affiliate hospitals in Japan.13 None of our patients
were immunocompromised; that is, there were no
patients with HIV infection, patients with neutro-
penia secondary to chemotherapy or patients on
immunosuppressants, patients from nursing homes
or patients with recent (o30 days) admission to
hospital. The diagnosis was based on clinical signs
and symptoms (cough, fever, productive sputum,
dyspnea, chest pain or abnormal breath sounds),
and radiographic pulmonary abnormalities that
were at least segmental and were not due to
preexisting or other known causes. Concerning the
hospitalized patients, all cases of pneumonia
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occurring more than 3 days after hospitalization
were considered nosocomial and were excluded.
Microbiologic laboratory tests
Blood cultures and nasopharyngeal swab specimens
were obtained from all patients and, if pleural fluid
and sputum were available, a Gram’s stain test and
a quantitative culture were obtained. Sputum data
were only evaluated when the Gram’s stain test
revealed numerous leukocytes (425 in a  100
microscopic field) and few squamous epithelial
cells (o10 in a  100 microscopic field). Certain
invasive methods such as bronchoscopic examina-
tion were employed to obtain specimens in some
patients after full explanation of the procedures.
These specimens were also used for culturing of M.
pneumoniae and Legionella species on pleuropneu-
monia-like organism agar (70% Mycoplasma agar
base (Becton Dickinson Microbiology Systems, MD,
USA), 20% horse serum, 10% fresh yeast extract,
thallium acetate (final concentration 0.5mg/ml)
and sterile penicillin G (final concentration 1000U/
ml) and buffered charcoal-yeast extract alpha agar,
respectively. Cultures for C. pneumoniae and
Chlamydia psittaci were performed in cyclohex-
imide-treated HEp-2 cells.16,17 The specimens were
placed in a sucrose-phosphate-glutamate (SPG)
transport medium. Each specimen in the SPG
medium was sonicated and briefly centrifuged
(900 g for 10min) and then the supernatant was
overlayed on confluent monolayers of HEp-2 cells
grown on round coverslips (14mm in diameter) set
in 24-well cell culture plastic plates. The plates
were centrifuged at 1200 g for 60min at room
temperature. Next, 1ml of a culture medium
consisting of Eagle’s minimal essential medium
(Nissui Pharmaceuticals Co, Tokyo, Japan), 10%
heat-inactivated fetal calf serum (Gibco BRL Life
Technologies Inc, Grand Island, NY, USA) and
cycloheximide (Nakarai Tesque Inc, Tokyo, Japan)
at a final concentration of 1 mg/ml was applied.
Then the plates were incubated in 5% CO2 at 351C
for 72 h and all specimens were passaged twice.
Following incubation, a genus-specific fluorescein
isothiocyanate-conjugated monoclonal antibody
(Chlamydia FA Seiken; Denka Seiken, Tokyo, Japan)
and C. pneumoniae species-specific monoclonal
antibodies were used to stain inclusions.16,17 Inclu-
sion bodies formed in the cells were observed with
a Nikon epifluorescence microscope at  200 or
 400 magnification.
Paired serum samples were collected at intervals
of at least 4 weeks (range, 4 to 12 weeks; average,
5 weeks) after onset. Complement fixation tests
were done in all patients for antibodies to influenza
A and B viruses, adenovirus, respiratory syncytial
virus, cytomegalovirus, parainfluenza virus types 1,
2 and 3 and M. pneumoniae. Antibody to the
Legionella species was measured by the micro-
agglutination test (detection of L. pneumophila
serogroups 1–6, L. bozoemanii, L. dumoffii, L.
gormanii and L. micdadei) and Coxiella burnetii
was measured by the indirect immunofluorescence
test. The microimmunofluorescence (MIF) test was
employed for titration of IgG and IgM antibodies
against chlamydial species,18 using formalinized
elementary bodies of C. pneumoniae KKpn-15 and
TW-183, C. trachomatis L2/434/Bu and C. psittaci
6BC strains as antigens. Rheumatoid factors were
absorbed with Gullsorb (Gull Laboratories, Salt
Lake City, UT, USA) before IgM titrations. In
addition to serology and/or culturing, the urinary
antigen test (Binax NOW, Portland, MN, USA) was
used for detection of S. pneumoniae and L.
pneumophila.
Criteria for determination of microbial
etiology
The microbial etiology was classified as ‘‘defini-
tive’’, ‘‘presumptive’’ or ‘‘unknown’’. Bacteria
were considered to be definitive causative agents
when isolated from blood or pleural fluid cultures.
We considered the results of sputum cultures in
combination with Gram’s stain findings. An organ-
ism showing heavy (X107 cfu/ml) or moderate
(106 cfu/ml) growth of a predominant bacterium on
a sputum culture was considered to be a presump-
tive pathogen. Any microorganism isolated from
bronchoalveolar lavage fluid was considered to be a
presumptive pathogen when its concentration
reached 4105 cfu/ml in quantitative culture. If
M. pneumoniae or the Legionella species were
isolated from a specimen, that specimen was
considered to be a definitive pathogen even if the
culture showed little growth. L. pneumophila and
S. pneumoniae were considered to be a presump-
tive agent when the urinary antigen test was
positive.
For serologic tests, a four-fold rise in the anti-
body titer level between paired sera was consid-
ered definitive. C. pneumoniae and C. psittaci
infection was defined as IgM X1:32 or a four-fold
rise in IgG or IgM.19
Differential diagnosis
The Japanese guidelines propose a scoring system
to differentiate between bacterial and atypical
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pneumonia.9 The guidelines set up nine parameters
based on clinical symptoms, physical signs and
laboratory data. Six of these parameters are
concerned with clinical and physical examination;
(1) under 60 years old, (2) no underlying disease,
(3) an outbreak of pneumonia is currently in the
family or community, (4) the patient has parox-
ysmal cough, (5) the patient has a relatively slow
pulse rate in relation to the fever and (6) the
patient has absence of abnormal physical examina-
tion of the chest. Three parameters are related to
biological and radiological examination; (7) a
normal WBC count (o10,000/mm3), (8) a chest
radiograph showing a ground glass opacity (pattern)
and (9) detection of no organisms in the sputum by
Gram’s stain. When there is a correlation of items
of more than three parameters among the clinical
symptoms and physical signs or of items of more
than five parameters among clinical symptoms,
physical signs and laboratory data, then the guide-
lines recommend the use of macrolides or tetra-
cyclines for a suspected atypical pneumonia. If
these criteria are not met, the guidelines recom-
mend the use of b-lactams for a suspected bacterial
pneumonia.
Statistical analysis
Statistical analysis was done by Fisher’s exact test.
A mean age comparison was done by Student’s t-
test.
Results
The patients who fulfilled the diagnostic criteria for
pneumonia caused by S. pneumoniae, H. influen-
zae, C. pneumoniae or M. pneumoniae, which are
the top four leading causes of CAP in Japan,10–13
formed the groups for comparison of the guidelines.
Five hundred ninety-eight CAP patients were
enrolled in this study. Among all CAP cases, there
were 144 cases where a bacterium, S. pneumoniae
and/or H. influenzae (10 cases were blood culture
positive), was the pathogen identified by the panel
of diagnostic tests used, 91 cases where C.
pneumoniae was identified and 103 cases where
M. pneumoniae was identified. Of the 91 cases
of C. pneumoniae, 71 demonstrated four-fold or
greater rises in IgG antibody titers, while 41 cases
demonstrated four-fold or greater rises in IgM
antibody titers (21 cases met both criteria). All
cases of M. pneumoniae demonstrated four-fold
antibody seroconversion (31 cases were culture
positive).
Among the 91 cases of C. pneumoniae, C.
pneumoniae was the only pathogen identified in
53 cases (58.2%), while one or more additional
etiological factors were found in 38 cases (41.8%).
Table 1 shows the distribution of etiologies among
the 38 cases of mixed-C. pneumoniae pneumonia.
As for M. pneumoniae cases, M. pneumoniae was
the only pathogen identified in 86 cases (83.5%),
while one or more additional etiological factors
were found in 17 cases (16.5%). Table 2 shows the
distribution of etiologies among the 17 cases of
mixed-M. pneumoniae pneumonia. Recently, we
reviewed 62 cases of community-acquired C.
pneumoniae pneumonia and noted that the clinical
presentation of CAP cases with multiple pathogens
and cases in whom C. pneumonaie was the only
pathogen identified differed.16 These findings were
also confirmed in another study.17 In this study,
therefore, we divided the C. pneumoniae or M.
pneumoniae pneumonia cases into two groups:
those in whom C. pneumoniae or M. pneumoniae
was the only pathogen identified (pure-C. pneumo-
niae or pure-M. pneumoniae pneumonia) and those
with mixed-C. pneumoniae or mixed-M. pneumo-
niae pneumonia with other bacteria (excluding five
cases of concomitant infection with M. pneumoniae
or C. pneumoniae) in order to analyze the
differential diagnosis of the Japanese CAP guide-
lines.
Fig. 1 shows the age distribution and Table 3
shows the backgrounds of the patients with the
three etiological agents of CAP, bacteria (S.
pneumoniae and/or H. influenzae), C. pneumoniae
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Table 1 Frequency distribution of additional
etiologies of community-acquired pneumonia in
91 patients infected with C. pneumoniae.
Pathogens Cases no.
Streptococcus pneumoniae 11
Haemophilus influenzae 5
Mycoplasma pneumoniae 5
Moraxella catarrahalis 2
Legionella pneumophila 2
Klebsiella pneumoniae 1
Staphylococcus aureus 1
S. PneumoniaeþH. influenzae 4
S. Pneumoniaeþ S. aureus 2
S. PneumoniaeþM. pneumoniae 1
S. PneumoniaeþM. catarrahalis 1
H. influenzaeþ S. aureus 1
M. Pneumoniaeþ S. aureus 1
S. aureusþM. catarrahalis 1
Single agentn 53
nC. pneumoniae was the only pathogen identified.
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and M. pneumoniae. Analysis of the age distribution
of the CAP patients in our study showed that while
CAP affects adults of all ages, the mean age of the
patients with bacterial pneumonia and mixed-C.
pneumoniae pneumonia (65.1 and 64.8 years) was
significantly higher than that of those with pure-C.
pneumoniae (54.7 years; P¼ 0.001), pure-M. pneu-
moniae (35.1 years; P¼ 0.0001) and mixed-M.
pneumoniae (45.5 years; P¼ 0.001) pneumonia.
The mean age of the patients with pure-C.
pneumoniae pneumonia was also significantly high-
er than that of those with pure-M. pneumoniae
(P¼ 0.0001) pneumonia. There were no statisti-
cally significant differences in terms of gender or
smoking history between the patients with mixed-
C. pneumoniae and those with bacterial pneumo-
nia, but the frequencies of a smoking history with
pure-C. pneumoniae and M. pneumoniae pneumo-
nia were significantly lower than those of mixed-C.
pneumoniae and bacterial pneumonia. Regarding
prognostic factors, no patients required respiratory
support and/or admission to an intensive care unit
(ICU) and no patients died among the patients with
pure-C. pneumoniae or M. pneumoniae pneumonia.
Table 4 shows the accordance rate with each
parameter of the guideline criteria in patients with
atypical pneumonia and bacterial pneumonia. In
both atypical pneumonia, high prevalence rates
were observed in the first (under 60 years old),
second (no underlying disease), fourth (the patient
has paroxysmal cough), sixth (the patient has
absence of abnormal physical examination of the
chest), seventh (WBC count o10,000/mm3) and
ninth (no organisms have been detected in the
sputum by Gram’s stain or there is no sputum
production) criteria parameters. The accordance
rates of the other three parameters were almost
identical in both atypical pathogens but were low.
The accordance rate for a suspected atypical
pneumonia with the guideline criteria was 84.8% in
pure-M. pneumoniae pneumonia and 60.3% in pure-
C. pneumoniae pneumonia, but only 9.0% in
bacterial pneumonia, 12.1% in mixed-C. pneumo-
niae pneumonia and 16.6% in mixed-M. pneumoniae
pneumonia (Table 5). The sensitivity, specificity and
likelihood ratio of the guideline criteria for a
diagnosis of M. pneumoniae pneumonia were
84.8%, 90.9% and 9.318, respectively. The area
under the Receiver Operating Characteristic (ROC)
curve of the guideline criteria for a diagnosis of M.
pneumoniae pneumonia was 0.852. The sensitivity,
specificity and likelihood ratio of the guideline
criteria for a diagnosis of C. pneumoniae pneumo-
nia were lower than that of M. pneumoniae
pneumonia, being 60.3%, 90.9% and 6.626,
respectively. The area under the ROC curve of the
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Table 2 Frequency distribution of additional
etiologies of community-acquired pneumonia in
103 patients infected with M. pneumoniae.
Pathogens Cases no.
Streptococcus pneumoniae 7
Chlamydia pneumoniae 5
Haemophilus influenzae 2
Moraxella catarrahalis 1
S. pneumoniaeþC. pneumoniae 1
S. aureusþC. pneumoniae 1
Single agentn 86
nM. pneumoniae was the only pathogen identified.
Figure 1 Age distribution of the patients with the three etiological agents, Chlamydia pneumoniae, Mycoplasma
pneumoniae and bacteria, of community-acquired pneumonia.
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guideline criteria for a diagnosis of C. pneumoniae
pneumonia, which was 0.690, was also lower than
that of M. pneumoniae pneumonia.
Discussion
The JRS started to develop its guidelines in 1998
and published the guidelines for CAP in March
2000.9 The Japanese guidelines seek to address the
management of CAP according to disease severity.
Pneumonia is divided at first into three categories:
mild to moderately severe pneumonia, severe
pneumonia, and pneumonia under special condi-
tions and environments. The special circumstances
include eight conditions such as exposure to birds,
resulting in psittacosis, and hot spring or circulating
bath facility use, resulting in Legionnaire’s disease.
Mild to moderately severe pneumonia is further
divided under bacterial or atypical causative
pathogens using a differential table. The reason
for this differentiation is to identify classical
atypical pneumonia to treat it with macrolides or
tetracyclines and to treat the remainder with b-
lactams.9 In other words, it is our intention to treat
S. pneumoniae with b-lactams as much as possible.
Our reasons for doing so are based on the fact that
S. pneumoniae is highly and frequently resistant to
macrolides and tetracyclines in Japan,14,15 and that
it has a tendency to cause severe or fatal
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Table 3 Backgrounds of the patients with the three etiological agents of community-acquired pneumonia.
C. pneumoniae M. pneumoniae Bacteriaz
Pure Mixed Pure Mixed
n¼ 53 n¼ 33n n¼ 86 n¼ 12w n¼ 144
Mean age, years 54.7 64.8 35.1 45.5 65.1
range 17–88 33–88 16–78 16–75 19–87
Male:female 31:22 23:10 47:39 7:5 98:46
Smoking history (%) 30 (56.6) 22 (66.6) 30 (34.8) 6 (50.0) 90 (62.5)
Respirator support (%) 0 3 (9.0) 0 0 14 (9.7)
ICU admission (%) 0 3 (9.0) 0 0 10 (6.9)
Mortality (%) 0 1 (3.0) 0 0 6 (4.1)
nExcluding five pneumonia patients with M. pneumoniae.
wExcluding five pneumonia patients with C. pneumoniae.
zS. pneumoniae and/or H. influenzae.
Table 4 Accordance rate (%) with each item of the guideline criteria in patients with the three etiological agents
of community-acquired pneumonia.
C. pneumoniae M. pneumoniae Bacteriaz
Pure Mixed Pure Mixed
n¼ 53 n¼ 33n n¼ 86 n¼ 12w n¼ 144
1. Age o60 years 60.3 27.2 83.7 50.0 25.6
2. No underlying disease 64.1 45.4 84.8 33.3 22.2
3. Pneumonia outbreaks in the family or community 11.3 0 12.7 0 0
4. Paroxysmal cough 64.1 30.3 75.5 33.3 34.7
5. Relatively slow pulse rate in relation to the fever 9.4 6.0 19.7 0 7.6
6. Absence of abnormal chest examination 79.2 12.1 79.0 16.6 18.0
7. WBC counto10,000/mm3 84.9 39.3 84.8 16.6 22.2
8. Ground glass pattern on chest radiograph 39.6 36.3 37.2 25.0 29.8
9. No pathogens in Gram’s stain or no sputum 86.7 12.1 90.6 8.3 9.7
nExcluding five pneumonia patients with M. pneumoniae.
wExcluding five pneumonia patients with C. pneumoniae.
zS. pneumoniae and/or H. influenzae.
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pneumonia. In cases suspected to be of bacterial
origin, the JRS recommends the sputum Gram’s
stain or other rapid diagnostic tests such as the
urine antigen test.
The clinical presentation of community-acquired
C. pneumoniae pneumonia has been investigated in
several countries.5,20–26 In those studies, the
diagnostic criteria for pneumonia caused by
C. pneumoniae were a four-fold or greater increase
in the titer for any Ig class of antibodies to
C. pneumoniae between paired serum samples or
an IgG titer of ^1:512, or the presence of IgM
(^1:16) antibodies for any serum sample examined
by the MIF test.18 In addition, some studies
included a high IgA titer as one of the diagnostic
criterion of acute C. pneumoniae pneumonia.23,24
However, the employment of criteria using the
single serum antibody, IgG^1:512, is a controver-
sial issue because a high incidence of IgG^1:512
has been seen among healthy asymptomatic sub-
jects.27–29 We have also made the same observa-
tion.30 Further, the criteria for the definition of IgA
levels as indicative of acute infection have not
been established. Based on these facts, the Centers
for Disease Control and Prevention (CDC, USA) and
the Laboratory Centre for Disease Control (LCDC,
Canada) made a recommendation for the standar-
dization of C. pneumoniae assays.19 They recom-
mended that the MIF test remain the only currently
acceptable approach and discouraged the use of a
single elevated IgG titer for determining acute
infection. In this study, therefore, we excluded the
IgG titer ^1:512 and any IgA titer from our
diagnostic criteria in accordance with the CDC
and LCDC recommendation.
In addition, atypical pathogens have been re-
ported to cause pneumonia frequently in associa-
tion with other respiratory pathogens, mainly
S. pneumoniae.11–13,16,17,20,22–26 However, it has
been suggested that C. pneumoniae may not be the
primary cause of the pneumonia but it might
disrupt the normal clearance mechanisms, enabling
other pathogens to invade. C. pneumoniae has
been shown to have a ciliastatic effect on ciliated
bronchial epithelial cells in vivo.31 M. pneumoniae
also exerts a toxic effect on the ciliated human
epithelium.32 Further, we observed that the clinical
presentation of CAP cases with multiple pathogens
and cases in whom C. pneumonaie was the only
pathogen identified differed.16,17 Therefore, we
also believe that mixed cases of mild or asympto-
matic upper respiratory tract infections are prob-
ably induced by atypical pathogens and are
followed by secondary bacterial pneumonia due to
another proven etiology. In this study, in order to
analyze the clinical picture of pneumonia cases, we
divided the C. pneumoniae or M. pneumoniae
pneumonia cases into two groups: those in whom
C. pneumoniae or M. pneumoniae was the only
pathogen identified and those with mixed-C.
pneumoniae or pure-M. pneumoniae pneumonia.
Our results indicated that C. pneumoniae pneumo-
nia as a single etiological agent is mild to moderate
and that the clinical pictures, with the exception of
underlying conditions, closely resembled those of
M. pneumoniae pneumonia. On the other hand, the
clinical pictures of C. pneumoniae or M. pneumo-
niae pneumonia concomitant with other bacteria
differed remarkably from those of pneumonia cases
in which C. pneumoniae or M. pneumoniae was the
only pathogen identified but were similar to those
of bacterial pneumonia, such as S. pneumoniae
pneumonia. Our results differed from those of
previous reports and we suspected that it might be
possible to distinguish between C. pneumoniae or
M. pneumoniae and bacterial pneumonia.
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Table 5 Accordance rate for a suspected atypical pneumonia with the guideline criteria in patients with the
three etiological agents of community-acquired pneumonia.
C. pneumoniae M. pneumoniae Bacteriaz
Pure Mixed Pure Mixed
n¼ 53 n¼ 33n n¼ 86 n¼ 12w n¼ 144
Clinical symptoms and physical signs
X 3 points (%) 32 (60.3) 4 (12.1) 73 (84.8) 2 (16.6) 13 (9.0)
Clinical symptoms and physical signs and laboratory data
X 5 points (%) 30 (56.6) 3 (9.0) 69 (80.2) 1 (8.3) 4 (2.7)
nExcluding five pneumonia patients with M. pneumoniae.
wExcluding five pneumonia patients with C. pneumoniae.
zS. pneumoniae and/or H. influenzae.
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It is well known that differentiation between
atypical and bacterial pneumonia is not always
possible in the initial diagnosis.3,5,23–25 However,
the JRS demonstrated that it would be possible to
distinguish between M. pneumoniae and bacterial
pneumonia in preliminary studies using the guide-
line criteria.9 Recently, Ishida et al. evaluated the
JRS scoring system to differentiate atypical pneu-
monia from bacterial pneumonia and they demon-
strated that about 81% of M. pneumoniae and 92%
of bacterial pneumonia could be distinguished using
the guideline criteria.11 In this study, we also
assessed the JRS guidelines with regard to whether
we could distinguish between atypical pneumonia
and bacterial pneumonia and confirmed that about
85% of pure-M. pneumoniae and more than 90% of
bacterial pneumonia could be distinguished using
the guideline criteria. Our results were quite
consistent with former these results. On the other
hand, the accordance rate in patients with pure-C.
pneumoniae pneumonia was 60% and lower than
that of pure-M. pneumoniae pneumonia. The
different accordance rates between C. pneumoniae
and M. pneumoniae were based on underlying
conditions such as age and underlying diseases
(Tables 3, 4). Therefore, we also assessed the
guidelines when the patients were under 60 years
old and high accordance rates were observed in
patients with both atypical pneumonia. However,
for 30% of patients under 60 years old, the
guidelines could lead to an inappropriate initial
empirical antimicrobial therapy since the sus-
pected atypical pneumonia was, in fact, a bacterial
pneumonia. That findings indicated that the guide-
line criteria should not be used for the differential
diagnosis of CAP in patients under 60 years old
because of the low specificity.
In both atypical pneumonia, high accordance
rates were observed in the fourth (the patient has
paroxysmal cough), sixth (the patient has absence
of abnormal physical examination of the chest),
seventh (WBC count o10,000/mm3), and ninth (no
organisms have been detected in the sputum by
Gram’s stain or there is no sputum production)
criteria parameters. However, regarding the third
guideline criteria parameter (an outbreak of
pneumonia is currently in the family or commu-
nity), there have been many reports of outbreaks of
C. pneumoniae infection in families, schools,
military barracks and nursing homes worldwide.18
We have also encountered outbreaks of C. pneu-
moniae infection in some schools and families, and
have also encountered outbreaks of M. pneumoniae
infection in families.33 But the incidence of
pneumonia outbreaks has not been very high. We
believe, however, that the occurrence of outbreaks
in families or groups is a very important feature of
both C. pneumoniae and M. pneumoniae infection
and should be included as a reference. Further-
more, the prevalence rates for a relatively slow
pulse rate in relation to the fever reported in
association with other intracellular infections such
as legionellosis and psittacosis were low in both
C. pneumoniae and M. pneumoniae pneumonia. In
addition, the sixth (the patient has absence of
abnormal physical examination of the chest) and
eighth (chest radiograph shows a ground glass
pattern) criteria parameters were subjective fac-
tors. Individual medical doctors may differ in their
judgment concerning them. It seems, therefore,
that some items in the criteria should be excluded
or changed to objective factors. However, we did
not evaluate other atypical pathogens, such as
Chlamydia psittaci, Coxiella burnetti and Legio-
nella species, in this study because their incidence
is low and they are not common pathogens in
Japan.10–13 In the future, we will have to accumulate
pneumonia cases caused by these atypical pathogens
and analyze the clinical presentation to assess whether
some items in the criteria of the JRS guidelines should
be excluded or words should be changed.
In conclusion, our results indicated that the
differentiation of pneumonia in the JRS guidelines
is useful for the diagnosis of M. pneumoniae
pneumonia as a single etiological agent, but
difficult for the diagnosis of C. pneumoniae
pneumonia. However, JRS scoring system to differ-
entiate atypical pneumonia from bacterial pneu-
monia may hardly be transferrable to the situation
in Western countries.
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